IMV (NYSE:IMV)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report issued on Monday, AnalystRatings.com reports. They presently have a $11.50 target price on the stock. HC Wainwright’s price target suggests a potential upside of 306.36% from the company’s previous close.
A number of other equities analysts have also recently issued reports on IMV. Raymond James set a $10.00 target price on IMV and gave the stock an “outperform” rating in a report on Thursday, November 7th. Oppenheimer assumed coverage on IMV in a report on Monday, November 25th. They set an “outperform” rating for the company. Wells Fargo & Co initiated coverage on IMV in a research report on Monday, October 28th. They issued a “market perform” rating for the company. Echelon Wealth Partners reissued a “buy” rating and issued a $12.25 price target on shares of IMV in a research note on Tuesday, November 12th. Finally, Zacks Investment Research downgraded IMV from a “hold” rating to a “sell” rating in a report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $9.60.
NYSE IMV opened at $2.83 on Monday. IMV has a 1 year low of $2.11 and a 1 year high of $6.02. The business’s fifty day moving average is $2.64 and its two-hundred day moving average is $2.98.
Institutional investors have recently bought and sold shares of the stock. Hartford Financial Management Inc. lifted its stake in IMV by 9.6% in the 3rd quarter. Hartford Financial Management Inc. now owns 38,098 shares of the company’s stock worth $94,000 after acquiring an additional 3,348 shares in the last quarter. Royal Bank of Canada increased its stake in IMV by 3.6% in the 2nd quarter. Royal Bank of Canada now owns 98,676 shares of the company’s stock valued at $288,000 after buying an additional 3,453 shares during the period. Citadel Advisors LLC acquired a new position in IMV in the 2nd quarter valued at approximately $37,000. Bank of Montreal Can lifted its position in IMV by 17.5% in the 2nd quarter. Bank of Montreal Can now owns 88,889 shares of the company’s stock worth $260,000 after buying an additional 13,228 shares in the last quarter. Finally, Morgan Stanley lifted its position in IMV by 260.5% in the 2nd quarter. Morgan Stanley now owns 90,368 shares of the company’s stock worth $264,000 after buying an additional 65,300 shares in the last quarter.
IMV Company Profile
IMV, Inc is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm’s patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.
Further Reading: What is Depreciation?
Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.